[Link Fixed] Australia's Ministry of Health has provisionally switched CBD from prescription-only to OTC status to widen access in the absence of any safety concerns and to encourage companies to undertake much-needed clinical trials to prove efficacy for CBD in low doses. However, switch expert Natalie Gauld thinks these expensive trials, and therefore approved Australian OTC CBD products, may not be forthcoming.

A wide-ranging study of low-dose cannabidiol supplementation, its regulation, efficacy and safety calls for improved legislation, guidelines and quality control together with clinical trials exploring the increasingly popular ingredient's therapeutic benefits.

Stada Arzneimittel is looking for local partners and/or acquisition opportunities in the US to expand its offer and quickly establish its presence in the country, Stada executive vice president Roger Scarlett-Smith tells HBW Insight in this exclusive interview.